MedPage Today included HelioLiver in its roundup of the latest news across gastroenterology and hepatology. Among a range of clinical updates, the roundup highlighted new findings on Helio Genomics’ blood test for the early detection of liver cancer, published in the Journal of Hepatology.
According to the item, a multi-analyte, cell-free DNA-based blood test, HelioLiver Dx, demonstrated superior sensitivity and non-inferior specificity compared with ultrasound for the early detection of liver cancer, including small lesions. The finding adds to the evidence that a simple blood test can help catch hepatocellular carcinoma earlier than imaging alone, which often misses the small, early-stage tumors that matter most for treatment.
For clinicians following advances in liver cancer surveillance, the mention places HelioLiver within the broader clinical conversation about earlier, less invasive detection. Because so many at-risk patients miss recommended ultrasound screening, a blood-based option that performs well on small and early tumors could help close important gaps in care.
Source: MedPage Today. Read the full roundup.